Dr. Kylie A. McLaughlin PhD has 15 years of experience in the field of biomedical science and oncology. She holds the distinction of being the first scientist to join the CV6 Therapeutics R&D in Northern Ireland in 2015. She currently holds the position of Associate-Principal Scientist within the R&D team.

Kylie’s research expertise spans drug development, drug resistance mechanisms, DNA damage, cell death, and nucleotide metabolism. Since joining CV6, she has been actively involved in small molecular inhibitor screening and the pre-clinical evaluation of candidate compounds within the CV6 pipeline. Importantly, Kylie has played a key role in the pre-clinical research supporting the development of CV6-168 up to the Phase 1a Clinical Trial Application submission. Currently, her research focus is on translating mechanism-of-action knowledge to the development and validation of pharmacodynamic biomarkers for the CV6 pipeline.

Kylie attained a first-class degree in Biomedical Science (BSc Hons) from Queen’s University Belfast and was a recipient of the President’s Prize for outstanding achievement by the Institute of Biomedical Science. Kylie completed her doctoral research in 2015 under the guidance of Professors Dan Longley and Kevin Prise within Prof. Patrick G. Johnston’s lab where she was identifying mechanisms of chemotherapy and radiotherapy resistance in lung cancer. In 2017, she was admitted as a Fellow of the Institute of Biomedical Science.